Irish hospitals will be offered a €500 (US $561) incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.
Irish hospitals will be offered a €500 (US $561) incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.
The Irish Times reports that the incentives, which will be paid to hospitals rather than to individual prescribers, are part of an effort to switch half of Irish patients receiving these drugs to cost-saving options.
If successful, the approach could save approximately €50 million (US $56 million) in drug costs, and €8.7 million (US $9.7 million) of those savings would be put back into the national healthcare system.
Ireland is undertaking the program in response to low rates of switching to biosimilars, despite the availability of biosimilar options to these 2 high-cost therapies; since biosimilar etanercept became available, it has captured just 1.8% of the market for etanercept.
Ireland’s Medicines Management Program (MMP), a body that promotes cost-effective drug prescribing, began an evaluation process in early 2019 under which it reviewed the use of currently reimbursed anti—tumor necrosis factor (anti-TNF) therapies, which the MMP’s roadmap for prescribing best-value biologics noted represent the highest-expenditure category for Ireland’s reimbursement plan, comprising nearly one-third of drug spending.
Then, in May 2019, the MMP released its guide to best-value biologics for anti-TNFs. The guide recommends that prescribers use Samsung Bioepis’ Imraldi (which as an acquisition price of €623.46, or US $700, for a pack of 2 40-mg injections in prefilled syringes) in place of brand-name Humira (after rebate, €781.48, or US $878), or the citrate-free Amgevita, sold by Amgen (€662.83, or US $744) if needed.
In place of brand-name Enbrel (with an after-rebate acquisition cost of €358.29, or US $402, for a pack of 4 prefilled syringes with doses of 25 mg each), MMP recommends prescribing Samsung Bioepis’ Benpali (€354.53, or US $389). These recommendations apply to new start and to already-treated patients.
According to the MMP, acquisition costs, indications, formulation, product ranges (including pack sizes and strengths), administration devices, supply to the Irish market, and other relevant factors were considered in developing these recommendations.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.